The U.S. Food and Drug Administration has stated that Capricor Therapeutics’ stem cell candidate for Duchenne muscular dystrophy, known as deramiocel, did not meet the objectives of a Phase 3 trial. This determination, released by the agency in documents published ahead of an advisory committee meeting, contradicts Capricor’s public assertion in December that the trial achieved both its primary and secondary endpoints.
The source notes that Capricor had described the trial results as a striking outcome in a fatal childhood disease that has remained difficult to treat despite advances in genetic medicine. The FDA’s documented position, published prior to a hearing where agency advisers will review the drug, indicates the agency views the study as falling short of its stated objectives.
According to the material made public by the FDA, the agency disagreed with the company’s interpretation of the Phase 3 data. Capricor had announced last December that deramiocel met both primary and secondary endpoints in a large, randomized study. The STAT coverage reproduced in the source reports the FDA’s contrary conclusion, and it notes that the documents were released in advance of an advisory meeting where outside experts will weigh in on the application.
The source does not provide granular data from the trial, such as endpoint definitions, numerical results, statistical analyses, or the FDA’s detailed rationale beyond the headline conclusion that the study did not meet objectives. Those detailed findings and the advisory committee’s deliberations are not included in the publicly available portion of the article.
A new report from UNAIDS, cited in the source, warns that the world faces the risk of an HIV resurgence after a significant drop in international financing for HIV control in 2025. The report found that government funding for HIV declined by more than $1.5 billion to $7.3 billion in 2025, representing an 18% reduction and the lowest funding level in nearly two decades.
The STAT summary highlighted in the source emphasizes that the cut in funding represents a “profound shock” to programs that have relied heavily on external financing. The public summary stresses the potential public-health consequences, including erosion of prevention programs that depend on sustained donor investment.
The UNAIDS material noted, and the STAT excerpt reproduces, that many prevention programs historically rely heavily on donor assistance. In sub-Saharan Africa, donor contributions for prevention reached 83% two years prior, illustrating the region’s vulnerability to reductions in international funding.
The source also reports that while the United States was criticized for funding cuts, it nevertheless accounted for 74% of government donor funding for HIV. The STAT write-up reproduces these figures from the UNAIDS report but does not furnish additional breakdowns by country, programmatic area, or funding mechanisms.
The Pharmalittle column excerpt in the source is identified as a STAT+ exclusive. The publicly available portion covers the FDA’s position on Capricor’s Duchenne therapy and the UNAIDS funding report. The article signals additional items and deeper coverage — for example, the original headline referenced GSK cost savings and other items — but those sections are behind the STAT+ paywall.
Because the source text presented here is truncated and marked as exclusive content, specific details about other topics alluded to in the headline (including any GSK cost-savings plan or additional analysis) were not reported in the publicly available portion of the article. Readers seeking the full set of items, any supporting data, and further context are directed in the source to subscribe or log in to STAT+ to view the remainder of the column.